Related Experiment Video
Updated: Jun 28, 2026
09:57
Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
Published on: February 14, 2011
11.9K
Challenges to Implementing a Vaccine for Coccidioidomycosis
Bridget M Barker1, George R Thompson2, Neil M Ampel3
1Department of Biological Sciences, Northern Arizona University, Flagstaff, Arizona, USA.
Open Forum Infectious Diseases
|June 18, 2024
Summary
A new coccidioidomycosis vaccine is coming soon. This paper addresses key questions about its use, including vaccination goals, target populations, immunity measurement, and overcoming vaccine hesitancy for successful public health impact.
Area of Science:
- Medical research
- Vaccinology
- Infectious diseases
Background:
- Coccidioidomycosis, a fungal infection, poses a significant public health challenge.
- A vaccine for coccidioidomycosis is anticipated to enter clinical trials soon.
- Pre-vaccine implementation research is crucial for optimizing vaccine efficacy and uptake.
Purpose of the Study:
- To identify and address critical questions prior to the widespread use of a coccidioidomycosis vaccine.
- To propose solutions for key considerations in vaccine deployment and public acceptance.
Main Methods:
- The study outlines four pivotal questions requiring answers before vaccine deployment.
- It provides proposed solutions and frameworks for each identified question.
Main Results:
- The four core questions concern: 1) defining vaccination goals, 2) identifying target populations, 3) establishing methods to measure vaccine-induced immunity and protection, and 4) strategies for addressing vaccine hesitancy and denial.
Conclusions:
- Answering these questions is essential for the successful and equitable implementation of a coccidioidomycosis vaccine.
- Proactive planning and research will maximize the public health benefits of this forthcoming vaccine.
Related Concept Videos
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:23Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
01:24Smallpox
Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.
01:27Cryptococcal Meningitis
Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
01:28Toxoplasmosis
Toxoplasmosis, a zoonotic disease caused by the protozoan Toxoplasma gondii, poses significant public health challenges globally due to its high seroprevalence and varied clinical manifestations. As an obligate intracellular parasite, T. gondii can infect all warm-blooded vertebrates, but felids are its only definitive hosts, shedding unsporulated oocysts into the environment. Humans typically acquire the infection through ingestion of tissue cysts in undercooked meat or oocysts from...